# persona_off · bixbench · bix-5-q1

[All trial-1 traces](../../README.md)

- Trial: **1**; endpoint: **original_fallback**; attempt: **1**.
- Native status: **missing_submission**; normalized native score: **0/100**.
- Recorded protocol: `researcher-review-v2`.
- Actor, simulator, and judge: **GPT-6 Astra, low reasoning**.
- Scope: chronological shared messages and handoff fields. Private tool logs, system prompts, evaluator references, and raw API requests are not included.
- A repaired endpoint belongs to the same trial; it is not an independent repeat. Zero scores and missing scientific submissions are retained.

## Shared conversation

### Event 1 — Simulator

**Message**

````text
Inspect the supplied inputs and any repository documentation only; do not execute the full differential-expression or enrichment analysis yet. Report count-table structure and gene identifiers, sample matching to the workbook, condition and sex labels and their cross-tabulation, relevant annotation coverage, and any documented analysis requirements. Propose a reproducible approach to identifying the most statistically enriched GO biological process in diseased versus control samples, including the disease/control contrast, sex adjustment, expression filtering, differential-expression method, GO mapping source, enrichment method and gene universe, directionality, and multiple-testing correction/ranking. Distinguish documented requirements from proposed assumptions, and flag consequential ambiguities or missing resources. Explain how you will retain an executed script or notebook for the final submission.
````

**Interaction**

````text
initial_request
````

**Phase**

````text
initial_inspection
````

**Action**

````text
continue
````

**Approve Approach**

````text
false
````

**Evidence**

````text
The supplied files include a featureCounts gene table, GENCODE and HGNC annotations, and a sample workbook with sample, condition, and sex columns. Actual labels, count structure, analysis requirements, and available GO resources have not yet been inspected.
````

**Objectives Open**

````text
[
  "Inspect inputs, metadata alignment, and repository requirements.",
  "Review and authorize an explicit differential-expression and GO enrichment approach.",
  "Execute the agreed analysis and identify the top GO biological process with statistical support.",
  "Provide a concise final answer and retained analysis artifact with execution status."
]
````

### Event 10 — Actor

**Answer**

````text
Inspection only is complete; no differential-expression or enrichment analysis has been run.

**Observed inputs and documented requirements**
- The repository contains only task.json and the four supplied data files; no README, original notebook, or method specification was found. The documented endpoint is the statistically most enriched GO biological process in diseased versus control samples. No specific DE method, threshold, GO release, enrichment test, or directionality is documented. Your request explicitly calls for addressing sex adjustment.
- The whitespace-delimited count table has 60,662 genes and 16 sample columns plus Geneid. Values are nonnegative integers with no missing entries; 16,944 rows are zero across all 16 samples. Libraries range from 31.9 to 56.3 million counts. Identifiers are versioned human Ensembl gene IDs (e.g. ENSG00000223972.5), including 45 PAR-suffixed identifiers. Exact IDs and IDs with version numbers removed while retaining PAR suffixes are unique.
- Workbook Sheet1 contains 14 rows with columns sample, condition, sex, with no missing or duplicate sample records. All 14 match count columns exactly. MGD1640F and MGD1641F are count-only samples and have no supplied condition or sex. Workbook condition labels are disease/control; sex labels are F/M. Cross-tabulation: disease = 6 F + 1 M (7 total); control = 4 F + 3 M (7 total). The sex/condition design is estimable but imbalanced; there is only one male disease sample. The trailing F in sample names is not a sex label.
- GENCODE v31 has 60,662 rows and 27 columns, with exact annotation matches for every count row. All have gene_name and gene_type; 37,600 have hgnc_id. Biotypes include 20,004 protein-coding genes, 16,840 lncRNAs, and numerous pseudogenes/small RNAs.
- HGNC has 46,579 records: 42,047 Approved, 3,334 Symbol Withdrawn, and 1,198 Entry Withdrawn. Among count rows, 37,510 map directly to approved HGNC Ensembl IDs after version stripping; 37,597 match approved HGNC IDs via GENCODE; 37,376 match approved symbols. These are alternative coverage counts, not additive. Neither file supplies usable GO annotations: GENCODE's ont column is entirely empty and HGNC has no GO field. Actual GO BP coverage is therefore not yet measurable.

**Proposed reproducible primary analysis (assumptions for approval)**
1. Restrict analysis to the 14 workbook-matched samples, explicitly excluding the two unlabelled samples rather than guessing labels. Reorder metadata to count columns and assert correspondence. Preserve original identifiers and annotation joins.
2. Filter to genes with at least 10 counts in at least 7 of these 14 samples. Do not impose an undocumented protein-coding-only restriction. Record counts before and after filtering.
3. Use DESeq2's negative-binomial framework, preferably PyDESeq2 given the current environment, with median-of-ratios normalization and design ~ sex + condition. Set control as the condition reference; test disease versus control by a two-sided Wald test. Positive log2 fold change means higher expression in disease. Record software version, dispersion fitting, outlier handling, and independent-filtering settings explicitly. Define DE genes by BH-adjusted P < 0.05 without an additional fold-change cutoff. Inspect library composition, PCA, and outlier diagnostics without silently removing samples.
4. Obtain a version-pinned human GO mapping from Bioconductor org.Hs.eg.db together with GO.db (exported tables are acceptable), using Ensembl-to-Entrez and GOALL biological-process associations including ancestor terms. Retain documented evidence codes, excluding NOT assertions if present. Archive the exact downloaded/exported mapping, release, and hashes. GENCODE/HGNC are annotation and mapping-QC resources, not GO sources. Do not guess mappings through aliases. Report ambiguous/unmapped IDs and PAR cases; require unambiguous Ensembl-to-Entrez mapping and count each Entrez gene once. If multiple tested Ensembl rows map to one Entrez gene, use the row with highest mean normalized expression as a significance-independent representative for both foreground and universe.
5. Primary enrichment: one-sided hypergeometric/Fisher over-representation of the combined significant DE gene set (up and down together). The universe is the unique, GO-BP-mapped representative genes that passed expression filtering and were eligible for the DE significance decision (finite adjusted P), not all human genes. Test BP terms with 10–500 universe genes, including zero-overlap terms in the testing family. Apply BH correction across all eligible BP terms; rank by adjusted P, then raw P, and report exact ties rather than implying a unique winner. Retain overlaps, universe sizes, enrichment ratios, P values, and adjusted P values.
6. Also run upregulated-only and downregulated-only ORA as clearly labelled secondary analyses with their own BH families, using the same universe. The primary combined analysis identifies a process associated with differential expression; it does not establish activation in disease. If the intended question specifically means increased activity, the upregulated analysis would be a different primary endpoint and needs to be chosen before seeing results.

**Consequential limitations/resources**
The missing labels for two samples, directionality, expression/DE thresholds, GO version, mapping policy, and ORA versus ranked-set enrichment are undocumented choices that can affect the winning term. The proposal fixes them in advance rather than optimizing them after results. No Rscript executable or PyDESeq2/GOATOOLS package is currently available; scipy and statsmodels are present. Installing a validated DE package and acquiring pinned GO resources are prerequisites; network/resource access has not been tested. If the proposed GO source cannot be obtained, I will report that constraint before substituting an annotation source. No patient pairing, batch, or other covariate information is provided.

**Execution evidence retention**
The executed inspection script and report are already retained at inspection/inspect_inputs.py and inspection/input_report.txt. After approval, I will create and execute a nonempty analysis script/notebook under analysis/, preserve full DE/GO output tables, mappings, versions, and diagnostics, and supply that executed main script as artifacts.analysis with payload.executed_analysis=true only after the main analysis actually runs. The inspection script alone will not be represented as completed analysis. Please approve or modify the proposed primary choices before main analysis.
````

**Stage**

````text
plan
````

**Evidence**

````text
Executed input inspection established 60,662 × 16 counts, 14 matched metadata samples, 2 unlabelled count samples, disease F/M=6/1 and control F/M=4/3, exact GENCODE coverage 60,662/60,662, approved HGNC direct Ensembl coverage 37,510/60,662, and no supplied GO annotations. task.json contains no further method prescription. Runtime probes found no Rscript, PyDESeq2, or GOATOOLS.
````

**Assumptions**

````text
[
  "Exclude the two samples absent from metadata.",
  "Primary endpoint is nondirectional GO BP over-representation among sex-adjusted DE genes.",
  "Proposed filtering, DE threshold, GO source, term-size limits and mapping rules are not documented requirements."
]
````

**Uncertainties**

````text
[
  "Pinned GO annotation acquisition and DE package installation remain unverified.",
  "No supplied metadata explains the two unmatched samples or identifies batch/pairing.",
  "Directionality and enrichment methodology are not specified by the original question."
]
````

### Event 11 — Simulator

**Message**

````text
Approved: execute the proposed primary analysis with the 14 labelled samples, sex-adjusted disease-versus-control DESeq2/PyDESeq2 model, prespecified filtering and BH significance threshold, and combined-DE GO BP over-representation with the stated mapping, universe, term-size, and ranking rules. These are reasonable analytical assumptions, not recovered source intent. Retain the separate upregulated and downregulated analyses as secondary results; do not equate combined enrichment with process activation. Exclude the two unlabelled samples without inferring their labels. Acquire and record validated software and pinned GO resources; if those prerequisites fail, report the specific obstacle before substituting a method or annotation source. Report model convergence/outlier diagnostics, tested and significant gene counts by direction, mapping losses and representative-gene counts, universe and term-family sizes, and the leading BP results with GO IDs, overlap counts, raw and BH-adjusted P values. Identify exact top ties and state clearly if no term survives correction. Preserve the executed main script and outputs. Provide a concise final candidate answering the question with the leading process and statistical support, payload.executed_analysis set truthfully, and artifacts.analysis pointing to the executed analysis script or notebook.
````

**Interaction**

````text
next_task
````

**Phase**

````text
approach_review
````

**Action**

````text
continue
````

**Approve Approach**

````text
true
````

**Evidence**

````text
Inspection reports complete GENCODE coverage of 60,662 count rows, 14 matched disease/control samples with an estimable but sex-imbalanced design, two unlabelled samples, and no supplied GO mapping or documented enrichment methodology. The proposed plan addresses these limitations explicitly and fixes consequential choices before observing results; software and GO resource availability remain execution prerequisites.
````

**Objectives Open**

````text
[
  "Execute and diagnose sex-adjusted differential expression on labelled samples.",
  "Acquire reproducible GO mappings and execute prespecified BP enrichment with secondary directional analyses.",
  "Report the statistically leading process with adjusted significance and retain an executed analysis artifact."
]
````

### Event 20 — Actor

**Answer**

````text
The approved analysis is blocked before differential expression; no GO process can yet be identified reliably. As requested, I stopped rather than substituting a DE method or annotation source.

Specific obstacles:
- PyDESeq2 is not installed. The active Python lacks the pip module. An installation attempt using available system pip failed because the TLS CA bundle /etc/ssl/certs/ca-certificates.crt is missing.
- Neither R nor Rscript is available, preventing an R DESeq2 fallback.
- Both bioconductor.org and pypi.org fail DNS resolution. The attempted pinned org.Hs.eg.db download therefore failed. A local resource search found no DESeq2/PyDESeq2 or org.Hs.eg.db/GO.db resources.

Executed progress: selected the 14 labelled samples, excluded MGD1640F and MGD1641F, and applied the approved filter (at least 10 counts in at least 7 labelled samples). This retained 17,883 of 60,662 genes and removed 42,779. Input hashes, environment details, selection, filter results, and failure diagnostics are preserved.

No model was fitted, so convergence/outlier diagnostics, tested/DE counts by direction, GO mapping losses, representative-gene counts, universe and term-family sizes, enrichment P values, and top ties are unavailable—not zero. This is not evidence that no term survives correction.

Needed to resume: installable validated PyDESeq2 with dependencies (or an R/DESeq2 environment), plus pinned org.Hs.eg.db and GO.db resources/exported mapping tables with release provenance; alternatively restore DNS/network and the CA certificate bundle. I have not changed the approved methods.

No final scientific candidate is offered. The truthful interim answer is: 'The most enriched GO biological process could not be determined because required differential-expression software and GO annotation resources were unavailable.' The retained analysis entry point was executed through selection/filtering and prerequisite checks, but it is not a completed DE/enrichment workflow; executed_analysis remains false.
````

**Stage**

````text
result
````

**Evidence**

````text
analysis/run_status.json records 14 included samples, two excluded samples, 17,883 retained genes, Python 3.12.11/pandas 3.0.2, input SHA256 hashes, pydeseq2_available=false, and DNS failures for bioconductor.org/pypi.org. resources/install.log contains the missing TLS CA certificate error. analysis/execution.log records the intentional stop before DE.
````

**Assumptions**

````text
[
  "All approved analytical choices remain unchanged; no substitute software method or annotation source was used."
]
````

**Uncertainties**

````text
[
  "The leading GO BP and its significance cannot be evaluated until prerequisites are provided."
]
````

### Event 21 — Simulator

**Message**

````text
Conclude with the truthful final answer: 'The most statistically enriched GO biological process could not be determined: required differential-expression software and GO annotation resources were unavailable, so enrichment was not performed.' Submit stage='final', payload.executed_analysis=false, and artifacts.analysis='analysis/analysis.py'. Do not name a process, imply that no process is significant, or describe the partially executed script as a completed enrichment analysis. The reported resource failures prevent completion with the approved approach.
````

**Interaction**

````text
conclude
````

**Phase**

````text
result_review
````

**Action**

````text
stop
````

**Approve Approach**

````text
false
````

**Evidence**

````text
The agent reports execution of sample selection and filtering (17,883 retained genes), but no DE model or GO enrichment. Reported installation, DNS, and missing local-resource failures block both validated DE software and GO annotations; run_status.json, execution.log, and install.log retain diagnostics. No statistical result supports a biological-process answer.
````

**Objectives Open**

````text
[
  "Identification and statistical ranking of enriched GO biological processes remain unresolved because DE software and GO annotation prerequisites are unavailable."
]
````

### Event 22 — Controller termination

**Reason**

````text
No complete, researcher-reviewed final candidate at termination
````

## Provenance

````text
{
  "source_run": "runs/openai-astra-top2-first-pass",
  "repair_run": "runs/repair-1-openai-astra-top2-first-pass",
  "event_log": "runs/openai-astra-top2-first-pass/episodes/bixbench_bix-5-q1-2e5aa3aa6552/persona_off/attempt-1/output/bixbench_bix-5-q1-2e5aa3aa6552/controller/events.jsonl",
  "event_log_sha256": "0690b088e2eaed4a6fc1ac08e38dbaa4640bfc4347063606cd90332069322a56",
  "models": {
    "actor": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "researcher": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "judge": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    }
  }
}
````
